<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-15" updated="2019-12-02">
  <drugbank-id primary="true">DB08455</drugbank-id>
  <name>Ro 12-7310</name>
  <description/>
  <cas-number>65316-65-6</cas-number>
  <unii/>
  <average-mass>312.4028</average-mass>
  <monoisotopic-mass>312.172544634</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">(2E,4E,6E,8E)-9-(4-Hydroxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alkenes</category>
      <mesh-id>D000475</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carotenoids</category>
      <mesh-id>D002338</mesh-id>
    </category>
    <category>
      <category>Cyclohexanes</category>
      <mesh-id>D003510</mesh-id>
    </category>
    <category>
      <category>Cyclohexenes</category>
      <mesh-id>D053138</mesh-id>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Acyclic</category>
      <mesh-id>D006839</mesh-id>
    </category>
    <category>
      <category>Pigments, Biological</category>
      <mesh-id>D010860</mesh-id>
    </category>
    <category>
      <category>Polyenes</category>
      <mesh-id>D011090</mesh-id>
    </category>
    <category>
      <category>Retinoids</category>
      <mesh-id>D012176</mesh-id>
    </category>
    <category>
      <category>Terpenes</category>
      <mesh-id>D013729</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>3cbs</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The therapeutic efficacy of Estradiol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The therapeutic efficacy of Mestranol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Desogestrel can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Norethisterone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The therapeutic efficacy of Norgestimate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Drospirenone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Gestodene can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Dienogest can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>The therapeutic efficacy of Norgestrel can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Gestrinone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>The therapeutic efficacy of Quingestanol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>The therapeutic efficacy of Demegestone can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00162</drugbank-id>
      <name>Vitamin A</name>
      <description>The risk or severity of adverse effects can be increased when Vitamin A is combined with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>Valproic acid may increase the Pseudotumor Cerebri activities of Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Doxycycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Lymecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Clomocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Tigecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Oxytetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Demeclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Metacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Rolitetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Eravacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Omadacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Meclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Methotrexate is combined with Ro 12-7310.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.19e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2E,4E,6E,8E)-9-(4-hydroxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2E,4E,6E,8E)-9-(4-hydroxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>312.4028</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>312.172544634</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H24O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H24O3/c1-13(7-6-8-14(2)11-20(22)23)9-10-18-15(3)12-19(21)17(5)16(18)4/h6-12,21H,1-5H3,(H,22,23)/b8-6+,10-9+,13-7+,14-11+</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>CAAFTBWHFUPDGX-OFCLTBKTSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>57.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>99.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>36.52</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>5.01</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-5.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6438583</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99444926</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4943051</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>R12</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers>
    <carrier position="1">
      <id>BE0000782</id>
      <name>Cellular retinoic acid-binding protein 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29373" source="Swiss-Prot">
        <name>Cellular retinoic acid-binding protein 2</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Transports retinoic acid to the nucleus. Regulates the access of retinoic acid to the nuclear retinoic acid receptors.</specific-function>
        <gene-name>CRABP2</gene-name>
        <locus>1q21.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.07</theoretical-pi>
        <molecular-weight>15692.925</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2339</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CRABP2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M68867</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181026</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29373</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RABP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Cellular retinoic acid-binding protein II</synonym>
          <synonym>CRABP-II</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016206|Cellular retinoic acid-binding protein 2
MPNFSGNWKIIRSENFEELLKVLGVNVMLRKIAVAAASKPAVEIKQEGDTFYIKTSTTVR
TTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTRELTNDGEL
ILTMTADDVVCTRVYVRE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016207|Cellular retinoic acid-binding protein 2 (CRABP2)
ATGCCCAACTTCTCTGGCAACTGGAAAATCATCCGATCGGAAAACTTCGAGGAATTGCTC
AAAGTGCTGGGGGTGAATGTGATGCTGAGGAAGATTGCTGTGGCTGCAGCGTCCAAGCCA
GCAGTGGAGATCAAACAGGAGGGAGACACTTTCTACATCAAAACCTCCACCACCGTGCGC
ACCACAGAGATTAACTTCAAGGTTGGGGAGGAGTTTGAGGAGCAGACTGTGGATGGGAGG
CCCTGTAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGTGAGCAGAAGCTC
CTGAAGGGAGAGGGCCCCAAGACCTCGTGGACCAGAGAACTGACCAACGATGGGGAACTG
ATCCTGACCATGACGGCGGATGACGTTGTGTGCACCAGGGTCTACGTCCGAGAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00061</identifier>
            <name>Lipocalin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinal binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinol binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic forelimb morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of collateral sprouting</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of retinoic acid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>